| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/22/2011 | US7893042 Boc-glycyl-phenazopyridine; phenazopyridines covalently attached to various conjugates; useful for providing increased (oral) bioavailability with reduced side effects |
| 02/22/2011 | US7893041 Oligosaccharide compositions and use thereof in the treatment of infection |
| 02/22/2011 | US7893040 Cyclodextrin nanotechnology for ophthalmic drug delivery |
| 02/22/2011 | US7893039 Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents |
| 02/22/2011 | US7893038 Feeds contains alginate and an acceptable carriers; nutrients; weight gain |
| 02/22/2011 | US7893037 Compressed tablet formulation containing active ingredient 4'-azidocytidine-2', 3', 5'-tri-isobutyrate hydrochloride and ethylene glycol-propylene glycol block copolymer; gel inhibition during formulation; enhanced gastrointestinal dissolution and absorption; hepatitis C virus |
| 02/22/2011 | US7893036 In vivo production of small interfering RNAs that mediate gene silencing |
| 02/22/2011 | US7893035 Multicistronic constructs with siRNA to inhibit tumors |
| 02/22/2011 | US7893024 Enhancement of iron chelation therapy |
| 02/22/2011 | US7893021 Parathyroid hormone antagonists and uses thereof |
| 02/22/2011 | US7892834 Cellular signal-responsive gene transcriptional regulation system |
| 02/22/2011 | US7892833 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions |
| 02/22/2011 | US7892828 Method of identifying a MHC class I restricted T cell response |
| 02/22/2011 | US7892793 Allele-specific RNA interference |
| 02/22/2011 | US7892782 Screening process for antibacterial agents |
| 02/22/2011 | US7892773 Expression vector comprising nucleotide sequences coding homeobox transcriptional regulator gene for identifying modulators for treatment and prevention of cell proliferative disorders of urogenital system |
| 02/22/2011 | US7892661 Substrate with a photocatalytic coating |
| 02/22/2011 | US7892582 Composition for oral administration containing capsaicinoids |
| 02/22/2011 | US7892574 Topical administration of oxazolidinones for transdermal delivery |
| 02/22/2011 | US7892549 Treatment with anti-ErbB2 antibodies |
| 02/22/2011 | US7892539 Modulation of an innate immune response by altering TRIAL-R signaling |
| 02/22/2011 | US7892530 Treatment of tumor metastases and cancer |
| 02/22/2011 | US7892483 Sterilization process |
| 02/22/2011 | CA2601515C Compounds having immunomodulator activity |
| 02/22/2011 | CA2565096C Method for the production of trans- or cis-diammoniumdichlorodihydroxoplatinum(iv) and the use thereof for the production of pharmaceutical agent |
| 02/22/2011 | CA2558501C 4-anilinoquinazolines derivatives with adenosine-kinase inhibitory properties |
| 02/22/2011 | CA2553879C Viral polymerase inhibitors |
| 02/22/2011 | CA2551409C Prostaglandin nitrooxyderivatives |
| 02/22/2011 | CA2540678C Pharmaceutical compositions for prevention of overdose or abuse |
| 02/22/2011 | CA2533509C Piperidine compounds and pharmaceutical compositions containing them |
| 02/22/2011 | CA2510096C Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
| 02/22/2011 | CA2501021C Pantethine-containing particulate |
| 02/22/2011 | CA2486378C Preparation and application of total salvianolic acid |
| 02/22/2011 | CA2485909C Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| 02/22/2011 | CA2484159C Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase |
| 02/22/2011 | CA2476296C Amino-derivatives as inhibitors of histone deacetylase |
| 02/22/2011 | CA2474823C Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| 02/22/2011 | CA2472093C Use of sulfated glycosaminoglycans for establishing effective labor in women |
| 02/22/2011 | CA2471310C An improved synthesis of ceftiofur intermediate |
| 02/22/2011 | CA2470575C Spiroazacyclic compounds as monoamine receptor modulators |
| 02/22/2011 | CA2468133C Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 02/22/2011 | CA2466726C Preparation composition containing acid-unstable physiologically active compound and process for producing same |
| 02/22/2011 | CA2463968C Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
| 02/22/2011 | CA2459857C Combinatorial type controlled release drug delivery device |
| 02/22/2011 | CA2447712C Herbal drug composition for cartilage protection |
| 02/22/2011 | CA2446314C Liver x receptor agonists |
| 02/22/2011 | CA2444062C Novel use of 2h-benzimidazol-2-one,1,3-dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts |
| 02/22/2011 | CA2435714C Fenofibrate tablets |
| 02/22/2011 | CA2435503C Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| 02/22/2011 | CA2429898C Devices and methods for cholesterol management |
| 02/22/2011 | CA2411818C Cyclopentabenzofuran compounds and uses thereof |
| 02/22/2011 | CA2410193C Neuronal serine-threonine protein kinase |
| 02/22/2011 | CA2403139C Novel 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and medicaments containing these compounds |
| 02/22/2011 | CA2398163C Therapeutic morpholino-substituted compounds |
| 02/22/2011 | CA2392685C Antisense antibacterial method and composition |
| 02/22/2011 | CA2359109C Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 02/22/2011 | CA2350882C Transfection reagents |
| 02/22/2011 | CA2329181C 12,13-modified epothilone derivatives |
| 02/22/2011 | CA2328438C Heterocyclically substituted amides, their production and their use |
| 02/22/2011 | CA2319198C Substituted oxoazaheterocyclyl factor xa inhibitors |
| 02/22/2011 | CA2263409C High molecular weight polymer-based prodrugs |
| 02/22/2011 | CA2223754C Actinomyces pyogenes and actinomyces pyogenes/fusobacterium necrophorum vaccines for immunizing cattle and sheep |
| 02/22/2011 | CA2185998C The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure |
| 02/22/2011 | CA2170644C Multiple unit pharmaceutical preparation containing proton pump inhibitor |
| 02/22/2011 | CA2137221C Preparation of 3,4,4-trisubstituted piperidinyl-n-alkylcarboxylates and intermediates |
| 02/18/2011 | CA2685321A1 Solubilized delivery system for topical anesthetics |
| 02/17/2011 | WO2011020116A1 Imidamide sphingosine kinase inhibitors |
| 02/17/2011 | WO2011020090A2 Compositions and methods for treating cancer |
| 02/17/2011 | WO2011020079A1 Antibodies against human respiratory syncytial virus (rsv) and methods of use |
| 02/17/2011 | WO2011020061A2 Compositions and methods of for treating bipolar disorder |
| 02/17/2011 | WO2011020044A1 Substituted triazolophthalazine derivatives |
| 02/17/2011 | WO2011020030A2 Methods and compositions to prevent addiction |
| 02/17/2011 | WO2011020001A2 Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases |
| 02/17/2011 | WO2011019995A2 Synthesis and identification of novel rsk-specific inhibitors |
| 02/17/2011 | WO2011019990A1 Use of e5501 for stimulating platelet production |
| 02/17/2011 | WO2011019986A2 Processes for preparing pemetrexed |
| 02/17/2011 | WO2011019956A2 Pharmaceutical compositions |
| 02/17/2011 | WO2011019942A2 Synthetic cholesterylamine-linker derivatives for agent delivery into cells |
| 02/17/2011 | WO2011019940A2 Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method for use |
| 02/17/2011 | WO2011019911A1 Intravenous formulations of neurokinin-1 antagonists |
| 02/17/2011 | WO2011019845A1 Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions |
| 02/17/2011 | WO2011019821A2 METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) |
| 02/17/2011 | WO2011019815A2 Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| 02/17/2011 | WO2011019798A1 Methods and compositions for treating leukemia |
| 02/17/2011 | WO2011019793A2 Individualized therapy of single gene disorders with genetically modified adult stem cells |
| 02/17/2011 | WO2011019782A1 Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists |
| 02/17/2011 | WO2011019780A1 Azaindazoles as btk kinase modulators and use thereof |
| 02/17/2011 | WO2011019747A1 Compositions and methods of treating chronic pain by administering propofol derivatives |
| 02/17/2011 | WO2011019738A1 Compounds and methods of use thereof |
| 02/17/2011 | WO2011019737A1 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| 02/17/2011 | WO2011019732A1 Methods for iontophoretically treating nausea and migraine |
| 02/17/2011 | WO2011019685A2 Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof |
| 02/17/2011 | WO2011019681A1 Selective sphingosine-1-phosphate receptor antagonists |
| 02/17/2011 | WO2011019680A1 Process for preparing 4-methyl-3-thienylamine hydrochloride |
| 02/17/2011 | WO2011019678A1 Isothiozoles for treating conditions of the eye |
| 02/17/2011 | WO2011019651A1 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| 02/17/2011 | WO2011019636A2 Methods and compositions for the treatment of cancers and pathogenic infections |
| 02/17/2011 | WO2011019634A2 Aryl substituted sulfonamide compounds and their use as anticancer agents |
| 02/17/2011 | WO2011019630A2 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors |
| 02/17/2011 | WO2011019618A1 Boron-containing small molecules as antiprotozoal agents |